BioXcel Therapeutics Inc. (BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, has a data readout to watch out for this quarter.
A phase III trial evaluating the safety of a 120-mcg dose of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting, dubbed SERENITY At-Home, is underway. The trial is fully enrolled with over 205 patients. An independent Data Safety Monitoring Board has recommended that the trial continue without modification.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.